Promacta (eltrombopag) Disease Interactions
There are 4 disease interactions with Promacta (eltrombopag):
Eltrombopag (Includes Promacta) ↔ hepatitis C
Severe Potential Hazard, Moderate plausibility. Applies to: Infectious Hepatitis
Eltrombopag has shown to increase the risk of hepatic decompensation in patients with chronic hepatitis C in treatment with interferon and ribavirin. Clinical trials reported that ascites and encephalopathy occurred more frequently on these patients than in the placebo arm. Patients with chronic hepatitis and receiving antiviral treatment should be closely monitored. The manufacturers also recommend to discontinue eltrombopag if the antiviral therapy is discontinued.
Eltrombopag (Includes Promacta) ↔ hepatotoxicity / hepatic dysfunction
Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Eltrombopag can cause liver enzyme elevations. Monitor ALT, AST and bilirubin prior to treatment initiation, and every 2 weeks during dose adjustment phase and then monthly. If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized. Treatment should be discontinued if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function, or greater or equal to 3 x baseline in patients with pretreatment transaminase elevations that are progressively increasing, persist for 4 weeks or more, also have an increase in bilirubin, or also have clinical symptoms of liver injury or hepatic decompensation.
Hepatic impairment influences the exposure to eltrombopag. The initial dose should be reduced in patients with chronic ITP or severe aplastic anemia who have hepatic impairment. No dose adjustment is required on patients with chronic hepatitis C and hepatic impairment.
Eltrombopag (Includes Promacta) ↔ cataracts
Moderate Potential Hazard, Moderate plausibility. Applies to: Cataracts
In clinical trials, eltrombopag developed or worsened cataracts in 7% of the patients receiving treatment. A baseline ocular examination prior to administration of eltrombopag is recommended, and regular monitoring for signs and symptoms of cataracts should be performed regularly during treatment.
Eltrombopag (Includes Promacta) ↔ thrombotic / thromboembolic complications
Moderate Potential Hazard, Moderate plausibility. Applies to: Thrombotic/Thromboembolic Disorder
Thromboembolic complications may result from increases in platelet counts with eltrombopag. Consider the potential for increased risk of thromboembolism when administering eltrombopag to patients with known risk factors for thromboembolism.
Promacta (eltrombopag) drug interactions
There are 202 drug interactions with Promacta (eltrombopag)
Promacta (eltrombopag) alcohol/food interactions
There are 2 alcohol/food interactions with Promacta (eltrombopag)
More about Promacta (eltrombopag)
- Promacta Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 4 Reviews
- Drug class: platelet-stimulating agents
- FDA Alerts (1)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.